CA2399505C - Formulations de calcitonine pour administration par voie nasale - Google Patents

Formulations de calcitonine pour administration par voie nasale Download PDF

Info

Publication number
CA2399505C
CA2399505C CA2399505A CA2399505A CA2399505C CA 2399505 C CA2399505 C CA 2399505C CA 2399505 A CA2399505 A CA 2399505A CA 2399505 A CA2399505 A CA 2399505A CA 2399505 C CA2399505 C CA 2399505C
Authority
CA
Canada
Prior art keywords
pharmaceutical composition
calcitonin
composition
citric acid
liquid pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2399505A
Other languages
English (en)
Other versions
CA2399505A1 (fr
Inventor
William Stern
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enteris Biopharma Inc
Original Assignee
Unigene Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22659737&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2399505(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Unigene Laboratories Inc filed Critical Unigene Laboratories Inc
Publication of CA2399505A1 publication Critical patent/CA2399505A1/fr
Application granted granted Critical
Publication of CA2399505C publication Critical patent/CA2399505C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Abstract

La présente invention concerne une composition pharmaceutique liquide comprenant de la calcitonine ou l'un de ses sels d'addition acides et de l'acide citrique ou l'un de ses sels, sous une concentration comprise entre 10 mM et 50 mM, laquelle composition convient pour l'administration par voie nasale.
CA2399505A 2000-02-04 2001-01-31 Formulations de calcitonine pour administration par voie nasale Expired - Fee Related CA2399505C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18024100P 2000-02-04 2000-02-04
US60/180,241 2000-02-04
PCT/US2001/003212 WO2001056594A1 (fr) 2000-02-04 2001-01-31 Formulations de calcitonine pour administration par voie nasale

Publications (2)

Publication Number Publication Date
CA2399505A1 CA2399505A1 (fr) 2001-08-09
CA2399505C true CA2399505C (fr) 2012-01-03

Family

ID=22659737

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2399505A Expired - Fee Related CA2399505C (fr) 2000-02-04 2001-01-31 Formulations de calcitonine pour administration par voie nasale

Country Status (6)

Country Link
US (3) US6440392B1 (fr)
EP (1) EP1251867A4 (fr)
CN (1) CN1183965C (fr)
AU (1) AU783952B2 (fr)
CA (1) CA2399505C (fr)
WO (1) WO2001056594A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1251867A4 (fr) 2000-02-04 2004-12-08 Unigene Lab Inc Formulations de calcitonine pour administration par voie nasale
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
WO2005000222A2 (fr) * 2003-05-30 2005-01-06 Amylin Pharmaceuticals, Inc. Nouveaux procedes et nouvelles compositions pour une administration amelioree par voie muqueuse de peptides et de proteines
CN1546169A (zh) * 2003-12-16 2004-11-17 上海医药工业研究院 一种降钙素经鼻干粉吸入剂及制备方法
ITMI20040235A1 (it) * 2004-02-13 2004-05-13 Therapicon Srl Preparazione farmaceutica per il cavo orale
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US8377863B2 (en) 2007-05-29 2013-02-19 Unigene Laboratories Inc. Peptide pharmaceutical for oral delivery
CN101549149B (zh) * 2008-09-17 2011-12-28 北京双鹭药业股份有限公司 一种新的降钙素的水溶液鼻用喷雾制剂
US20100256060A1 (en) * 2009-04-02 2010-10-07 Unigene Laboratories Inc. Peptide pharmaceuticals for nasal delivery
DK2964193T3 (da) 2013-03-05 2020-03-16 Enteris Biopharma Inc Lægemidler til oral indgivelse
WO2016115082A1 (fr) 2015-01-12 2016-07-21 Enteris Biopharma, Inc. Formes galéniques orales solides
CN108969754B (zh) * 2018-09-04 2019-06-21 深圳大佛药业股份有限公司 一种鲑降钙素鼻喷雾剂及其制备方法

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151276A (en) 1975-05-12 1979-04-24 Armour Pharmaceutical Company Method of suppressing gastric acid secretion by the oral administration of calcitonin
SE460638B (sv) * 1981-01-14 1989-11-06 Toyo Jozo Kk Suppositoriepreparat med foerbaettrad absorptionsegenskap
US4900730A (en) 1981-01-14 1990-02-13 Toyo Jozo Co., Ltd. Preparation which promotes the absorption of peptides
JPS5885813A (ja) 1981-11-17 1983-05-23 Toyo Jozo Co Ltd 吸収性良好な製剤
US5169849A (en) 1982-02-01 1992-12-08 Sandoz Ltd. Nasal pharmaceutical compositions
CH657779A5 (de) 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
US4476116A (en) 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
IL70489A0 (en) 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
CH657858A5 (de) 1983-06-27 1986-09-30 Ciba Geigy Ag Substanz aus der gruppe der calcitonine.
JPS61267528A (ja) 1984-11-26 1986-11-27 Yamanouchi Pharmaceut Co Ltd 吸収促進剤を含有するカルシトニン経鼻剤
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
IT1204400B (it) 1986-06-20 1989-03-01 Sclavo Spa Composizioni farmaceutiche contenente una calcitonina
US5938654A (en) 1987-06-25 1999-08-17 Alza Corporation Osmotic device for delayed delivery of agent
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
ES2061688T3 (es) 1987-11-13 1994-12-16 Smithkline Beecham Farma Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
US5026825A (en) 1988-09-08 1991-06-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Intranasal calcitonin formulations
US5514365A (en) 1988-10-11 1996-05-07 Schiapparelli Salute S.P.A. Pharmaceutical compositions comprising calcitonin for intranasal administration
US5725871A (en) 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
IT1231957B (it) 1989-09-15 1992-01-16 Esseti Chimico Farmaco Bio Composizioni farmaceutiche stabili a base di calcitonina.
ES2067624T3 (es) 1989-11-16 1995-04-01 Ph & T S R L Un procedimiento de preparacion de una composicion farmaceutica liquida para administracion nasal.
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
WO1991016929A1 (fr) 1990-05-10 1991-11-14 Novo Nordisk A/S PREPARATION PHARMACEUTIQUE CONTENANT DES n-GLYCOFUROLS ET DES n-ETHYLENE GLYCOLS
US5714167A (en) 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
JPH078806B2 (ja) 1990-08-16 1995-02-01 旭化成工業株式会社 カルシトニン類含有経鼻投与用乳剤
IT1243390B (it) 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
EP0489217A1 (fr) 1990-12-05 1992-06-10 Dr. A. Tosi Farmaceutici S.R.L. Composition de calcitonine pour l'administration intranasale
US5234906A (en) 1991-01-10 1993-08-10 Amylin Pharmaceuticals, Inc. Hyperglycemic compositions
IT1254707B (it) 1991-02-19 1995-10-09 Mediator Srl Uso topico della calcitonima per la preparazione di medicamenti nella cataratta idiopatica senile e una composizione farmaceutica che la contiene
GB9108634D0 (en) 1991-04-23 1991-06-12 Ciba Geigy Pharmaceutical compositions
JP3608802B2 (ja) * 1991-09-20 2005-01-12 第一サントリーファーマ株式会社 安定なカルシトニン医薬組成物及びその製造法
US5571788A (en) 1991-12-09 1996-11-05 Ciba-Geigy Corporation Stable calcitonin pharmaceutical compositions
US5534496A (en) 1992-07-07 1996-07-09 University Of Southern California Methods and compositions to enhance epithelial drug transport
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US5759566A (en) 1992-07-28 1998-06-02 Poli Industria Chimica Spa Microemulsion pharmaceutical compositions for the delivery of pharmaceutically active agents
US5654000A (en) 1992-07-28 1997-08-05 Poli Industria Chimica S.P.A. Pharmaceutical compositions for transmucosal delivery of peptides
FR2697022B1 (fr) 1992-10-19 1994-12-16 Pasteur Institut Antigènes de Plasmodium falciparum capables d'induire des anticorps protecteurs à large spectre - Application à la vaccination.
IT1255895B (it) 1992-10-20 1995-11-17 Laura Chiodini Composizioni farmaceutiche contenenti una calcitonina
JP3628713B2 (ja) 1993-06-07 2005-03-16 帝國製薬株式会社 生理学的に活性なペプチドを含有する膣投与製剤
SE9302135D0 (sv) 1993-06-18 1993-06-18 Kabi Pharmacia Ab New pharmaceutical composition
KR950007873A (ko) 1993-09-20 1995-04-15 후꾸하라 요시하루 생리 활성 물질 지속 방출형의 의약 제제
US5496801A (en) 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US5968899A (en) 1994-06-03 1999-10-19 Tsumura & Co. Medicinal compositions of peptides with EACA or tranexamic acid for enhanced mucosal absorption
US5670163A (en) 1994-06-20 1997-09-23 Kv Pharmaceuticals Company Long acting GI and esophageal protectant
EP0726075A1 (fr) * 1995-02-08 1996-08-14 Therapicon Srl Solutions pharmaceutiques salines non-inorganiques pour administration endonasale
US5912014A (en) 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5726154A (en) 1996-06-28 1998-03-10 University Of Utah Research Foundation Stabilization and oral delivery of calcitonin
US6440446B1 (en) 1998-04-22 2002-08-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Agent for anti-osteoporosis
US6153582A (en) 1998-11-05 2000-11-28 Bausch & Lomb Surgical, Inc. Defined serumfree medical solution for ophthalmology
US6149893A (en) * 1999-03-01 2000-11-21 Alfa Wassermann S.P.A. Pharmaceutical compositions containing calcitonin in a spray dosing feeder for intranasal administration
EP1251867A4 (fr) * 2000-02-04 2004-12-08 Unigene Lab Inc Formulations de calcitonine pour administration par voie nasale
US6524580B1 (en) 2000-02-15 2003-02-25 Allergan Sales, Inc. Method for treating thyroid disorders

Also Published As

Publication number Publication date
USRE40812E1 (en) 2009-06-30
EP1251867A4 (fr) 2004-12-08
AU783952B2 (en) 2006-01-05
USRE43580E1 (en) 2012-08-14
WO2001056594A1 (fr) 2001-08-09
AU3660401A (en) 2001-08-14
US6440392B1 (en) 2002-08-27
CN1183965C (zh) 2005-01-12
CN1422160A (zh) 2003-06-04
EP1251867A1 (fr) 2002-10-30
CA2399505A1 (fr) 2001-08-09

Similar Documents

Publication Publication Date Title
USRE43580E1 (en) Nasal calcitonin formulations
US5733569A (en) Galenic compositions comprising calcitonin and their use
JP4405666B2 (ja) 安定化テリパラチド溶液剤
EP0397447B1 (fr) Formulations pharmaceutiques
US5763398A (en) Nasal administration of desmopressin
GB2127689A (en) Calcitonin inhalation compositions
JPH09502424A (ja) 安定化製薬性ペプチド組成
US8138149B2 (en) Nasal calcitonin formulations containing chlorobutanol
EP0809512A1 (fr) Solutions pharmaceutiques salines non organiques a administration endonasale d'une calcitonine
US7893025B2 (en) Use of growth hormone releasing factor analogs in treating patients suffering from wasting
US20100256060A1 (en) Peptide pharmaceuticals for nasal delivery
AU2006299887A1 (en) PTH formulations and methods of use
JPH0354647B2 (fr)
JPS6357527A (ja) 薬剤の吸着防止方法
EP1779864A1 (fr) Preparation contenant de la pth pour administration trans-muqueuse
IE56602B1 (en) Galenic compositions comprising calcitonin and their use
GB2417202A (en) Pharmaceutical preparation comprising calcitonin
IE56601B1 (en) Galenic compositions comprising calcitonin and their use
KR20070031425A (ko) Ｐｔｈ를 함유하는 경점막 투여제

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20190131

MKLA Lapsed

Effective date: 20190131